Phyllis August, MD
Nephrology · New York, NYNPI 1437246527
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $96,475 of the $96,528 with a category attached, or 99.9%. 4 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 56.6% of the total. Among nephrology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 43 payments — averaging $2244.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$55K
- Intercept Pharmaceuticals, Inc.$37K
- Vertex$5K
- Idorsia Pharmaceuticals US Inc$52
Across 30 payments — averaging $772.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$13K
- Intercept Pharmaceuticals, Inc.$10K
What the payments were for
- Consulting fees$96,475100%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 21 | $54,668 |
| Intercept Pharmaceuticals, Inc. | 12 | $37,133 |
| Vertex | 9 | $4,675 |
| Idorsia Pharmaceuticals US Inc | 1 | $52 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCALIVA$37,133
How this compares
$96,528 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Eplerenone | 36 | $8,063 |
| Candesartan Cilexetil | 17 | $2,042 |
| Atorvastatin Calcium | 64 | $663 |
| Telmisartan | 31 | $577 |
| Torsemide | 17 | $457 |
| Amlodipine Besylate | 42 | $339 |
| Spironolactone | 17 | $242 |
| Rosuvastatin Calcium | 12 | $222 |
| Metformin Hcl | 18 | $89 |
| Alprazolam | 12 | $89 |
| Hydrochlorothiazide | 17 | $75 |
Paid to pharmacies, not to this prescriber.
Other nephrology in New York
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Steven CocaNew York$445K
- Jai RadhakrishnanNew York$369K
- Girish NadkarniNew York$281K
- James ChevalierNew York$202K
- David CharytanNew York$164K
- Kirk CampbellNew York$152K
- Andrew BombackNew York$106K
- Alan PerlmanNew York$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.